 CRANBURY, N.J., June 28, 2021 PRNewswire -- Palatin Technologies, Inc. Palatin NYSE American: PTN a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced the strengthening of its senior leadership team with three key executive management appointments: Michael B. 